global chemical giants such as narrow-moat BasF, Bayer , and E l du Pont, as well as wide-moat Monsanto ..... ingredients. The business has similarities with generic pharmaceuticals manufacturers with marketing and distribution key differentiating
May 7 (Reuters) - California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG 's...
value estimate for Isis Pharmaceuticals to $64 per share from ..... attractive deal terms from Bayer for ISIS-FXI Rx, Isis ..... technology platform. We think Bayer will make a strong development ..... As part of the deal, Bayer will pay $100 million
FRANKFURT, May 4 (Reuters) - German drugmaker Bayer secured the rights to an experimental anti-blood-clotting drug in a deal with California-based Isis Pharmaceuticals to bolster its cardiovascular business led by blockbuster pill Xarelto.
* Says healthcare now expects sales to rise to over eur 24 billion (previously: approximately eur 23 billion)
EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche ..... Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other ..... Allergan Inc. - Ampio Pharmaceuticals Inc. - Antisense Therapeutics
of three segments: pharmaceuticals , consumer products ..... diseases. Eye-Care Pharmaceuticals Anti-VEGF treatments ..... Regeneron 's REGN and Bayer 's BAYRY Eylea and ..... Other eye-care pharmaceuticals include treatments
the prominent players in the global home healthcare market that have been profiled in the report include 3M Health Care, Bayer AG , Abbott Laboratories, Cardinal Health, Inc., GE Healthcare, Johnson & Johnson Services, Inc., Gentiva Health Services
Companies Involved in Therapeutics Development AstraZeneca PLC Bayer AG Incuron, LLC Novartis AG Otsuka Holdings Co., Ltd. Salivary ..... AstraZeneca PLC, H2 2014 Salivary Gland Cancer - Pipeline by Bayer AG , H2 2014 Salivary Gland Cancer - Pipeline by Incuron
Nov 24 (Reuters) - Germany-based drugmaker Bayer AG is considering the sale of its diabetes device business, Bloomberg reported, citing sources.